The epidemiology of Enterobacter gergoviae is the study of the distribution and determinants of the infections caused by this bacterium in human populations. Enterobacter gergoviae is a Gram-negative, motile, facultatively anaerobic, rod-shaped bacterium that belongs to the Enterobacter genus, which is a member of the ESKAPE group of resistant pathogens. It is of particular interest to the cosmetics industry, as it displays resistance to parabens, a common antimicrobial agent added to cosmetic products.
Enterobacter gergoviae is an uncommon human pathogen, most commonly as an opportunistic nosocomial infection. One hospital in Spain reported the organism to represent 0.4% of clinical Enterobacter isolates.
Risk factors for Enterobacter gergoviae infections include:
Prolonged hospital stays.
Immunosuppression.
The presence of a foreign device.
Prior use of antimicrobial agents in the patient involved.
Extremes of age.
Human infections caused by Enterobacter gergoviae include bacteremia, skin infections, infections of the lower respiratory tract & soft tissues, infections of the urinary system, and endocarditis, intraabdominal infections, septic arthritis, osteomyelitis, and ophthalmic infections.
Enterobacter gergoviae has been isolated from maize, grapes, coffee beans, spring water, fruit flies, and pink bollworms. It is also found in the environment, such as soil, water, and plants. The transmission of Enterobacter gergoviae to humans may occur through contact with contaminated sources, such as food, water, cosmetics, or medical devices.
Enterobacter gergoviae is resistant to many common antibiotics, such as penicillins, macrolides, lincosamides, streptogramins, rifampicin, fusidic acid, fosfomycin, and cefoxitin. Therefore, antibiotic susceptibility testing is recommended to guide the appropriate therapy. The development of antimicrobial resistance in Enterobacter gergoviae may involve various molecular mechanisms, such as enzymatic degradation, membrane efflux, target modification, and genetic regulation.
Kingdom: Bacteria
Phylum: Proteobacteria
Class: Gammaproteobacteria
Order: Enterobacterales
Family: Enterobacteriaceae
Genus: Enterobacter
Species: E. gergoviae
The structure of Enterobacter gergoviae can be summarized in five points as follows:
Enterobacter gergoviae is a type of bacteria that belongs to the family Enterobacteriaceae.
It is a gram-negative bacterium, which means that it does not retain the purple dye when stained with the Gram stain method.
It is a rod-shaped bacterium, which means that it has a cylindrical or elongated shape.
It is a motile bacterium, which means that it can move by using its peritrichous flagella, which are hair-like structures that surround the cell.
It is a facultatively anaerobic bacterium, which means that it can grow in both the presence and absence of oxygen.
The host defenses of Enterobacter gergoviae are:
Physical barriers: These are the structures that prevent the entry or attachment of the bacterium to the host tissues, such as the skin, mucous membranes, cilia, and mucus. Physical barriers can also expel the bacterium from the host, such as coughing, sneezing, or urination.
Chemical barriers: These are the substances that inhibit the growth or survival of the bacterium in the host, such as the acidic pH of the stomach, the lysozyme in the saliva and tears, the defensins and cathelicidins in the skin and mucous membranes, and the complement system in the blood. Chemical barriers can also kill or damage the bacterium, such as by generating reactive oxygen and nitrogen species or by forming membrane attack complexes.
Cellular barriers: These are the cells that recognize and eliminate the bacterium from the host, such as the phagocytes (neutrophils, monocytes, macrophages), the natural killer cells, the dendritic cells, and the mast cells. Cellular barriers can also activate the adaptive immune response, such as by presenting antigens, secreting cytokines, and stimulating lymphocytes.
Adaptive immunity: This is the specific and memory-based response that the host develops against the bacterium, such as the humoral immunity mediated by the B cells and the antibodies and the cellular immunity mediated by the T cells and the cytotoxic molecules. Adaptive immunity can also regulate the innate immune response, such as by enhancing or suppressing inflammation or by modulating the antigen presentation.
The clinical manifestations of Enterobacter gergoviae infections are:
Bacteremia: This is a condition where bacteria enter the bloodstream and cause systemic inflammation and sepsis. Symptoms may include fever, chills, low blood pressure, rapid heart rate, confusion, and organ failure.
Lower respiratory tract infections: These are infections that affect the lungs & airways, such as pneumonia, bronchitis, lung abscess, and empyema. Symptoms may include cough, chest pain, shortness of breath, sputum production, and fever.
Skin and soft tissue infections: They affect the skin and underlying tissues, such as cellulitis, wound infections, surgical site infections, and necrotizing fasciitis. Symptoms may include redness, swelling, pain, warmth, pus, and fever.
Urinary tract infections: These are infections that affect the kidneys, bladder, ureters, or urethra, such as pyelonephritis, cystitis, ureteritis, and urethritis. Symptoms may include burning, pain, frequency, urgency, blood, and fever.
Endocarditis: It affects the inner lining of the heart and the heart valves. Symptoms may include fever, chills, night sweats, weight loss, heart murmur, and embolic complications.
Intraabdominal infections: These are infections that affect the organs and structures within the abdominal cavity, such as peritonitis, abscess, appendicitis, diverticulitis, and cholecystitis. Symptoms may include abdominal pain, tenderness, distension, nausea, vomiting, and fever.
Septic arthritis: This is an infection that affects the elbow, shoulder, hip, and knee joints, among others. Symptoms may include joint pain, swelling, stiffness, reduced range of motion, and fever.
The diagnosis of Enterobacter gergoviae infection is based on the culture of the bacteria from the infected site, such as blood, urine, sputum, or wound. The bacteria can be identified by its biochemical and genetic characteristics, as well as its resistance to certain antibiotics.
The treatment of Enterobacter gergoviae infection depends on the type and severity of the infection, as well as the susceptibility of the bacteria to antibiotics—some of the antibiotics that are effective against Enterobacter gergoviae.
The prevention of Enterobacter gergoviae infection involves maintaining good hygiene, avoiding contact with contaminated sources, and following infection control measures in healthcare settings.
Here are some more specific tips on how to prevent Enterobacter gergoviae infection:
Wash your hands frequently with soap and water before and after eating, using the restroom, interacting with animals, or handling soil or plants.
Clean and cover any wounds or cuts with sterile dressings and change them regularly.
Disinfect any surfaces or objects that may have encountered soil, water, plants, or insects, such as gardening tools, pots, or shoes.
Avoid drinking or swimming in water that may be contaminated with Enterobacter gergoviae, such as ponds, lakes, or rivers.
Boil or filter any water that you use for drinking, cooking, or washing.
The epidemiology of Enterobacter gergoviae is the study of the distribution and determinants of the infections caused by this bacterium in human populations. Enterobacter gergoviae is a Gram-negative, motile, facultatively anaerobic, rod-shaped bacterium that belongs to the Enterobacter genus, which is a member of the ESKAPE group of resistant pathogens. It is of particular interest to the cosmetics industry, as it displays resistance to parabens, a common antimicrobial agent added to cosmetic products.
Enterobacter gergoviae is an uncommon human pathogen, most commonly as an opportunistic nosocomial infection. One hospital in Spain reported the organism to represent 0.4% of clinical Enterobacter isolates.
Risk factors for Enterobacter gergoviae infections include:
Prolonged hospital stays.
Immunosuppression.
The presence of a foreign device.
Prior use of antimicrobial agents in the patient involved.
Extremes of age.
Human infections caused by Enterobacter gergoviae include bacteremia, skin infections, infections of the lower respiratory tract & soft tissues, infections of the urinary system, and endocarditis, intraabdominal infections, septic arthritis, osteomyelitis, and ophthalmic infections.
Enterobacter gergoviae has been isolated from maize, grapes, coffee beans, spring water, fruit flies, and pink bollworms. It is also found in the environment, such as soil, water, and plants. The transmission of Enterobacter gergoviae to humans may occur through contact with contaminated sources, such as food, water, cosmetics, or medical devices.
Enterobacter gergoviae is resistant to many common antibiotics, such as penicillins, macrolides, lincosamides, streptogramins, rifampicin, fusidic acid, fosfomycin, and cefoxitin. Therefore, antibiotic susceptibility testing is recommended to guide the appropriate therapy. The development of antimicrobial resistance in Enterobacter gergoviae may involve various molecular mechanisms, such as enzymatic degradation, membrane efflux, target modification, and genetic regulation.
Kingdom: Bacteria
Phylum: Proteobacteria
Class: Gammaproteobacteria
Order: Enterobacterales
Family: Enterobacteriaceae
Genus: Enterobacter
Species: E. gergoviae
The structure of Enterobacter gergoviae can be summarized in five points as follows:
Enterobacter gergoviae is a type of bacteria that belongs to the family Enterobacteriaceae.
It is a gram-negative bacterium, which means that it does not retain the purple dye when stained with the Gram stain method.
It is a rod-shaped bacterium, which means that it has a cylindrical or elongated shape.
It is a motile bacterium, which means that it can move by using its peritrichous flagella, which are hair-like structures that surround the cell.
It is a facultatively anaerobic bacterium, which means that it can grow in both the presence and absence of oxygen.
The host defenses of Enterobacter gergoviae are:
Physical barriers: These are the structures that prevent the entry or attachment of the bacterium to the host tissues, such as the skin, mucous membranes, cilia, and mucus. Physical barriers can also expel the bacterium from the host, such as coughing, sneezing, or urination.
Chemical barriers: These are the substances that inhibit the growth or survival of the bacterium in the host, such as the acidic pH of the stomach, the lysozyme in the saliva and tears, the defensins and cathelicidins in the skin and mucous membranes, and the complement system in the blood. Chemical barriers can also kill or damage the bacterium, such as by generating reactive oxygen and nitrogen species or by forming membrane attack complexes.
Cellular barriers: These are the cells that recognize and eliminate the bacterium from the host, such as the phagocytes (neutrophils, monocytes, macrophages), the natural killer cells, the dendritic cells, and the mast cells. Cellular barriers can also activate the adaptive immune response, such as by presenting antigens, secreting cytokines, and stimulating lymphocytes.
Adaptive immunity: This is the specific and memory-based response that the host develops against the bacterium, such as the humoral immunity mediated by the B cells and the antibodies and the cellular immunity mediated by the T cells and the cytotoxic molecules. Adaptive immunity can also regulate the innate immune response, such as by enhancing or suppressing inflammation or by modulating the antigen presentation.
The clinical manifestations of Enterobacter gergoviae infections are:
Bacteremia: This is a condition where bacteria enter the bloodstream and cause systemic inflammation and sepsis. Symptoms may include fever, chills, low blood pressure, rapid heart rate, confusion, and organ failure.
Lower respiratory tract infections: These are infections that affect the lungs & airways, such as pneumonia, bronchitis, lung abscess, and empyema. Symptoms may include cough, chest pain, shortness of breath, sputum production, and fever.
Skin and soft tissue infections: They affect the skin and underlying tissues, such as cellulitis, wound infections, surgical site infections, and necrotizing fasciitis. Symptoms may include redness, swelling, pain, warmth, pus, and fever.
Urinary tract infections: These are infections that affect the kidneys, bladder, ureters, or urethra, such as pyelonephritis, cystitis, ureteritis, and urethritis. Symptoms may include burning, pain, frequency, urgency, blood, and fever.
Endocarditis: It affects the inner lining of the heart and the heart valves. Symptoms may include fever, chills, night sweats, weight loss, heart murmur, and embolic complications.
Intraabdominal infections: These are infections that affect the organs and structures within the abdominal cavity, such as peritonitis, abscess, appendicitis, diverticulitis, and cholecystitis. Symptoms may include abdominal pain, tenderness, distension, nausea, vomiting, and fever.
Septic arthritis: This is an infection that affects the elbow, shoulder, hip, and knee joints, among others. Symptoms may include joint pain, swelling, stiffness, reduced range of motion, and fever.
The diagnosis of Enterobacter gergoviae infection is based on the culture of the bacteria from the infected site, such as blood, urine, sputum, or wound. The bacteria can be identified by its biochemical and genetic characteristics, as well as its resistance to certain antibiotics.
The treatment of Enterobacter gergoviae infection depends on the type and severity of the infection, as well as the susceptibility of the bacteria to antibiotics—some of the antibiotics that are effective against Enterobacter gergoviae.
The prevention of Enterobacter gergoviae infection involves maintaining good hygiene, avoiding contact with contaminated sources, and following infection control measures in healthcare settings.
Here are some more specific tips on how to prevent Enterobacter gergoviae infection:
Wash your hands frequently with soap and water before and after eating, using the restroom, interacting with animals, or handling soil or plants.
Clean and cover any wounds or cuts with sterile dressings and change them regularly.
Disinfect any surfaces or objects that may have encountered soil, water, plants, or insects, such as gardening tools, pots, or shoes.
Avoid drinking or swimming in water that may be contaminated with Enterobacter gergoviae, such as ponds, lakes, or rivers.
Boil or filter any water that you use for drinking, cooking, or washing.
The epidemiology of Enterobacter gergoviae is the study of the distribution and determinants of the infections caused by this bacterium in human populations. Enterobacter gergoviae is a Gram-negative, motile, facultatively anaerobic, rod-shaped bacterium that belongs to the Enterobacter genus, which is a member of the ESKAPE group of resistant pathogens. It is of particular interest to the cosmetics industry, as it displays resistance to parabens, a common antimicrobial agent added to cosmetic products.
Enterobacter gergoviae is an uncommon human pathogen, most commonly as an opportunistic nosocomial infection. One hospital in Spain reported the organism to represent 0.4% of clinical Enterobacter isolates.
Risk factors for Enterobacter gergoviae infections include:
Prolonged hospital stays.
Immunosuppression.
The presence of a foreign device.
Prior use of antimicrobial agents in the patient involved.
Extremes of age.
Human infections caused by Enterobacter gergoviae include bacteremia, skin infections, infections of the lower respiratory tract & soft tissues, infections of the urinary system, and endocarditis, intraabdominal infections, septic arthritis, osteomyelitis, and ophthalmic infections.
Enterobacter gergoviae has been isolated from maize, grapes, coffee beans, spring water, fruit flies, and pink bollworms. It is also found in the environment, such as soil, water, and plants. The transmission of Enterobacter gergoviae to humans may occur through contact with contaminated sources, such as food, water, cosmetics, or medical devices.
Enterobacter gergoviae is resistant to many common antibiotics, such as penicillins, macrolides, lincosamides, streptogramins, rifampicin, fusidic acid, fosfomycin, and cefoxitin. Therefore, antibiotic susceptibility testing is recommended to guide the appropriate therapy. The development of antimicrobial resistance in Enterobacter gergoviae may involve various molecular mechanisms, such as enzymatic degradation, membrane efflux, target modification, and genetic regulation.
Kingdom: Bacteria
Phylum: Proteobacteria
Class: Gammaproteobacteria
Order: Enterobacterales
Family: Enterobacteriaceae
Genus: Enterobacter
Species: E. gergoviae
The structure of Enterobacter gergoviae can be summarized in five points as follows:
Enterobacter gergoviae is a type of bacteria that belongs to the family Enterobacteriaceae.
It is a gram-negative bacterium, which means that it does not retain the purple dye when stained with the Gram stain method.
It is a rod-shaped bacterium, which means that it has a cylindrical or elongated shape.
It is a motile bacterium, which means that it can move by using its peritrichous flagella, which are hair-like structures that surround the cell.
It is a facultatively anaerobic bacterium, which means that it can grow in both the presence and absence of oxygen.
The host defenses of Enterobacter gergoviae are:
Physical barriers: These are the structures that prevent the entry or attachment of the bacterium to the host tissues, such as the skin, mucous membranes, cilia, and mucus. Physical barriers can also expel the bacterium from the host, such as coughing, sneezing, or urination.
Chemical barriers: These are the substances that inhibit the growth or survival of the bacterium in the host, such as the acidic pH of the stomach, the lysozyme in the saliva and tears, the defensins and cathelicidins in the skin and mucous membranes, and the complement system in the blood. Chemical barriers can also kill or damage the bacterium, such as by generating reactive oxygen and nitrogen species or by forming membrane attack complexes.
Cellular barriers: These are the cells that recognize and eliminate the bacterium from the host, such as the phagocytes (neutrophils, monocytes, macrophages), the natural killer cells, the dendritic cells, and the mast cells. Cellular barriers can also activate the adaptive immune response, such as by presenting antigens, secreting cytokines, and stimulating lymphocytes.
Adaptive immunity: This is the specific and memory-based response that the host develops against the bacterium, such as the humoral immunity mediated by the B cells and the antibodies and the cellular immunity mediated by the T cells and the cytotoxic molecules. Adaptive immunity can also regulate the innate immune response, such as by enhancing or suppressing inflammation or by modulating the antigen presentation.
The clinical manifestations of Enterobacter gergoviae infections are:
Bacteremia: This is a condition where bacteria enter the bloodstream and cause systemic inflammation and sepsis. Symptoms may include fever, chills, low blood pressure, rapid heart rate, confusion, and organ failure.
Lower respiratory tract infections: These are infections that affect the lungs & airways, such as pneumonia, bronchitis, lung abscess, and empyema. Symptoms may include cough, chest pain, shortness of breath, sputum production, and fever.
Skin and soft tissue infections: They affect the skin and underlying tissues, such as cellulitis, wound infections, surgical site infections, and necrotizing fasciitis. Symptoms may include redness, swelling, pain, warmth, pus, and fever.
Urinary tract infections: These are infections that affect the kidneys, bladder, ureters, or urethra, such as pyelonephritis, cystitis, ureteritis, and urethritis. Symptoms may include burning, pain, frequency, urgency, blood, and fever.
Endocarditis: It affects the inner lining of the heart and the heart valves. Symptoms may include fever, chills, night sweats, weight loss, heart murmur, and embolic complications.
Intraabdominal infections: These are infections that affect the organs and structures within the abdominal cavity, such as peritonitis, abscess, appendicitis, diverticulitis, and cholecystitis. Symptoms may include abdominal pain, tenderness, distension, nausea, vomiting, and fever.
Septic arthritis: This is an infection that affects the elbow, shoulder, hip, and knee joints, among others. Symptoms may include joint pain, swelling, stiffness, reduced range of motion, and fever.
The diagnosis of Enterobacter gergoviae infection is based on the culture of the bacteria from the infected site, such as blood, urine, sputum, or wound. The bacteria can be identified by its biochemical and genetic characteristics, as well as its resistance to certain antibiotics.
The treatment of Enterobacter gergoviae infection depends on the type and severity of the infection, as well as the susceptibility of the bacteria to antibiotics—some of the antibiotics that are effective against Enterobacter gergoviae.
The prevention of Enterobacter gergoviae infection involves maintaining good hygiene, avoiding contact with contaminated sources, and following infection control measures in healthcare settings.
Here are some more specific tips on how to prevent Enterobacter gergoviae infection:
Wash your hands frequently with soap and water before and after eating, using the restroom, interacting with animals, or handling soil or plants.
Clean and cover any wounds or cuts with sterile dressings and change them regularly.
Disinfect any surfaces or objects that may have encountered soil, water, plants, or insects, such as gardening tools, pots, or shoes.
Avoid drinking or swimming in water that may be contaminated with Enterobacter gergoviae, such as ponds, lakes, or rivers.
Boil or filter any water that you use for drinking, cooking, or washing.
Enterobacter gergoviae | bacteria | Britannica
Pluralibacter gergoviae | Microchem Laboratory
Loading...
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
